Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Ellie Barnes and her team win a prestigious Cancer Research UK Early Detection Programme Award to research the earlier detection of hepatocellular carcinoma.

Image of liver scan

With this £2.5 million, five year award from Cancer Research UK (CRUK), Chief Investigator Ellie Barnes and her team aim to understand more about the changes in the liver as cancer develops and use this to inform new, more sensitive diagnostic tests with the ambition of detecting liver cancer earlier.

Liver cancer is the fastest rising cause of cancer death in the UK, with more than 5,000 deaths per year. Diagnosing liver cancer earlier, when current treatments are more effective, is critical for improving survival. However, this is challenging because symptoms are vague and late-presenting, and are frequently masked by co-occurring liver disease, such as cirrhosis. There are a number of conditions that increase the risk of liver cancer, including viral hepatitis, obesity and alcohol, leading to liver inflammation and cirrhosis. Surveillance of people at higher risk can reduce mortality but effectiveness is limited by the low sensitivity of current detection methods.

In this research programme, scientists aim to learn more about the origins of liver cancer and develop more sensitive detection tests. The Oxford-led team will investigate people with and without cancer to identify factors that will enable better risk assessment and earlier cancer detection. Their research will include analysis of molecular profiles in both the liver tissue and the blood, and advanced liver imaging.

Read more on the Oxford Centre for Early Cancer Detection website

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.